Northwest Biotherapeutics | NWBO - Gastos De Venta Y Administración





Gastos De Venta Y Administración Cambio Fecha
Agenus USD 10.56M 13.04M 2025-12
AstraZeneca USD 5.06B 455M 2026-03
Bristol-Myers Squibb USD 1.62B 564M 2026-03
Celldex Therapeutics USD 11.45M 3.61M 2026-03
Eisai JPY 119.54B 7.82B 2026-03
Merck USD 2.67B 180M 2026-03
Northwest Biotherapeutics USD 7.07M 1.06M 2025-09
Pfizer USD 2.92B 1.16B 2026-03
Plus Therapeutics USD 3.49M 559K 2025-12
Roche Holding CHF 7.28B 3.99B 2025-12